Tanzeum (albiglutide), a once-weekly injectable drug for type 2s from GSK (GlaxoSmithKline), USA is now available at pharmacies throughout the United States. The FDA approved U.S. sales on April 15. The drug is a glucagon-like peptide-1 receptor agonist (GLP-1) that can be used in conjunction with other type 2 drugs. GLP-1s work by inducing the … Continue reading Once-Weekly Tanzeum for Type 2s Now Available
The U.S. Food and Drug Administration reports that its review of various animal and human studies does not show a link between GLP-1 drugs used to treat type 2 diabetes and pancreatic maladies, including acute pancreatitis and pancreatic cancer. GLP-1 drugs, which work by stimulating the body to produce insulin, include Bristol-Myers Squibb’s Byetta and … Continue reading FDA Backtracks Over GLP-1s’ Effects on Pancreas
A recent agreement between Zosano Pharma, Inc. and Novo Nordisk could lead to the introduction of a once-weekly drug for type 2s that is administered via a micro-needle patch system. The drug, now under development by Novo Nordisk, is semaglutide, a GLP-1 (glucagon-like peptide) receptor agonist that the company is hoping to introduce as a … Continue reading Weekly Type 2 Drug to Be Delivered Via Needle Patch
Readers occasionally ask us for advice about drugs they are taking. When they do, we refer their questions to a medical professional. In the question below, a Florida reader expresses concerns about the interaction of her diabetes drug with the medicines she takes for asthma. Dear Diabetes Health: I am asthmatic and was diagnosed with … Continue reading Am I Doing the Right Thing?
Give us feedback about your experience with it
After several years of delays and setbacks, Amylin Pharmaceuticals has received FDA approval to begin US marketing of BydureonTM. The first once-a-week type 2 therapy to be offered in the US market, Bydureon is expected to be available by February. Amylin says that its wholesale price will be about $4,200 a year. The drug is … Continue reading FDA Gives Long-Awaited Nod to Amylin’s Bydureon